PE20220394A1 - Anticuerpos que se fijan a gprc5d - Google Patents

Anticuerpos que se fijan a gprc5d

Info

Publication number
PE20220394A1
PE20220394A1 PE2022000110A PE2022000110A PE20220394A1 PE 20220394 A1 PE20220394 A1 PE 20220394A1 PE 2022000110 A PE2022000110 A PE 2022000110A PE 2022000110 A PE2022000110 A PE 2022000110A PE 20220394 A1 PE20220394 A1 PE 20220394A1
Authority
PE
Peru
Prior art keywords
gprc5d
antibodies
bind
receptor
lymphocytes
Prior art date
Application number
PE2022000110A
Other languages
English (en)
Inventor
Alexander Bujotzek
Tony Christopeit
Tanja Fauti
Georg Fertig
Helène Cecile Haegel
Christian Klein
Thomas Kraft
Stefan Lorenz
Maud Lea Mayoux
Anneliese Schneider
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20220394A1 publication Critical patent/PE20220394A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion se refiere a anticuerpos biespecificos que se fijan al miembro D del grupo 5 de la clase C del receptor acoplado de la proteina G (GPRC5D), asi como al receptor CD3 para activar linfocitos T. La invencion tambien se refiere a polinucleotidos que codifican dichos anticuerpos, vectores, celulas huesped, composiciones farmaceuticas y metodos de produccion que comprenden tales anticuerpos. El receptor GPRC5D se expresa en celulas plasmaticas del mieloma multiple (MM) siendo util como diana de tratamiento, por tanto, los anticuerpos biespecificos de la invencion que se fijan a GPRC5D y a los linfocitos T tienen la potencia para tratar el MM.
PE2022000110A 2019-07-31 2020-07-28 Anticuerpos que se fijan a gprc5d PE20220394A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19189255 2019-07-31
PCT/EP2020/071182 WO2021018859A2 (en) 2019-07-31 2020-07-28 Antibodies binding to gprc5d

Publications (1)

Publication Number Publication Date
PE20220394A1 true PE20220394A1 (es) 2022-03-18

Family

ID=67513452

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000110A PE20220394A1 (es) 2019-07-31 2020-07-28 Anticuerpos que se fijan a gprc5d

Country Status (18)

Country Link
US (1) US20220259318A1 (es)
EP (1) EP4003526A2 (es)
JP (2) JP2022543553A (es)
KR (1) KR20220028035A (es)
CN (1) CN114174342A (es)
AR (1) AR119553A1 (es)
AU (1) AU2020323686B2 (es)
BR (1) BR112022001460A2 (es)
CA (1) CA3144524A1 (es)
CL (1) CL2022000127A1 (es)
CO (1) CO2022000803A2 (es)
CR (1) CR20220019A (es)
IL (1) IL287613A (es)
MX (1) MX2022001156A (es)
PE (1) PE20220394A1 (es)
SG (1) SG11202112491WA (es)
TW (1) TW202112823A (es)
WO (1) WO2021018859A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021007307A (es) 2018-12-21 2021-07-07 Hoffmann La Roche Anticuerpos que se unen a cd3.
TWI811703B (zh) 2020-06-19 2023-08-11 瑞士商赫孚孟拉羅股份公司 與ｃｄ３及ｃｄ１９結合之抗體
AU2021346129A1 (en) * 2020-09-16 2023-06-01 Janssen Biotech, Inc. Methods for treating multiple myeloma
CA3211070A1 (en) 2021-02-24 2022-09-01 F. Hoffmann-La Roche Ag Regeneration and multiple use of depth filters
WO2022247804A1 (zh) * 2021-05-23 2022-12-01 上海祥耀生物科技有限责任公司 抗gprc5d抗体、其制备方法与用途
CN118159565A (zh) * 2021-11-05 2024-06-07 正大天晴药业集团股份有限公司 结合gprc5d的抗体及其用途
CN116375868A (zh) * 2021-12-31 2023-07-04 康源博创生物科技(北京)有限公司 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用
WO2024002308A1 (zh) * 2022-06-30 2024-01-04 康诺亚生物医药科技（成都）有限公司 一种新型多特异肿瘤抑制剂的开发和应用
WO2024017326A1 (zh) * 2022-07-21 2024-01-25 山东先声生物制药有限公司 抗gprc5d纳米抗体及其应用
WO2024031091A2 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
WO2024079015A1 (en) 2022-10-10 2024-04-18 F. Hoffmann-La Roche Ag Combination therapy of a gprc5d tcb and imids
WO2024079010A1 (en) 2022-10-10 2024-04-18 F. Hoffmann-La Roche Ag Combination therapy of a gprc5d tcb and cd38 antibodies
WO2024079009A1 (en) 2022-10-10 2024-04-18 F. Hoffmann-La Roche Ag Combination therapy of a gprc5d tcb and proteasome inhibitors
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1096187A (en) 1977-04-18 1981-02-24 Souhei Monden Ornament adapted to be fixed by permanent magnets
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
JP3095175B2 (ja) 1992-11-13 2000-10-03 アイデック ファーマシューティカルズ コーポレイション Ｂ細胞リンパ腫の治療のためのヒトｂリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
JP2001521909A (ja) 1997-10-31 2001-11-13 ジェネンテク・インコーポレイテッド 糖タンパク質グリコフォームを含む方法及び組成物
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DE60022369T2 (de) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
WO2003085118A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede de production de composition anticorps
WO2003084570A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
WO2003085102A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cellule avec inhibition ou suppression de l'activite de la proteine participant au transport du gdp-fucose
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
KR20070055625A (ko) 2002-12-16 2007-05-30 제넨테크, 인크. 이뮤노글로불린 변이체 및 이들의 용도
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
CA2513797C (en) 2003-01-22 2016-05-03 Glycart Biotechnology Ag Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
EP1629012B1 (en) 2003-05-31 2018-11-28 Amgen Research (Munich) GmbH Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
KR100891620B1 (ko) 2004-04-13 2009-04-02 에프. 호프만-라 로슈 아게 항-ｐ-셀렉틴 항체
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
ES2755976T3 (es) 2005-02-07 2020-04-24 Roche Glycart Ag Moléculas de unión a antígeno que se unen a EGFR, vectores que las codifican y usos de las mismas
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
JP5686953B2 (ja) 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
JP5474531B2 (ja) 2006-03-24 2014-04-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 操作されたヘテロ二量体タンパク質ドメイン
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
US20080044455A1 (en) 2006-08-21 2008-02-21 Chaim Welczer Tonsillitus Treatment
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
RU2561457C2 (ru) 2007-04-03 2015-08-27 Эмджен Рисерч (Мьюник) Гмбх Cd3-эпсилон-связывающий домен с межвидовой специфичностью
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
PE20120591A1 (es) 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
PL2417156T3 (pl) 2009-04-07 2015-07-31 Roche Glycart Ag Trójwartościowe, bispecyficzne przeciwciała
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
JP5719354B2 (ja) 2009-05-27 2015-05-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 三重又は四重特異性抗体
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
WO2011034605A2 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
DK2519543T3 (en) 2009-12-29 2016-09-26 Emergent Product Dev Seattle HETERODIMER BINDING PROTEINS AND USE THEREOF
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
US9000130B2 (en) 2010-06-08 2015-04-07 Genentech, Inc. Cysteine engineered antibodies and conjugates
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
EP2691417B1 (en) 2011-03-29 2018-08-01 Roche Glycart AG Antibody fc variants
WO2013026833A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
RU2650775C2 (ru) 2011-08-23 2018-04-17 Рош Гликарт Аг Биспецифические антигенсвязывающие молекулы
KR101681818B1 (ko) 2011-08-23 2016-12-01 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
SI2794905T1 (sl) 2011-12-20 2020-08-31 Medimmune, Llc Modificirani polipeptidi za ogrodja bispecifičnega protitelesa
CA2860600C (en) 2012-02-15 2022-07-26 F. Hoffmann-La Roche Ag Fc-receptor based affinity chromatography
MX360110B (es) 2012-04-20 2018-10-23 Merus Nv Metodos y medios para la produccion de moleculas de tipo ig.
CN110845618A (zh) * 2013-02-26 2020-02-28 罗切格利卡特公司 双特异性t细胞活化抗原结合分子
EA201891502A1 (ru) 2013-02-26 2018-12-28 Роше Гликарт Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
CN114702594A (zh) 2013-12-20 2022-07-05 豪夫迈·罗氏有限公司 双重特异性抗体
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
JP6744292B2 (ja) 2014-07-29 2020-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
DK3177643T3 (da) 2014-08-04 2019-07-15 Hoffmann La Roche Bispecifikke T-celle-aktiverende antigenbindende molekyler
KR20170052600A (ko) 2014-09-12 2017-05-12 제넨테크, 인크. 시스테인 가공된 항체 및 콘주게이트
CA2963696A1 (en) * 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
WO2016062734A1 (en) 2014-10-24 2016-04-28 F. Hoffmann-La Roche Ag Vh-vl-interdomain angle based antibody humanization
SG10201913937QA (en) 2014-12-05 2020-03-30 Memorial Sloan Kettering Cancer Center Antibodies targeting g-protein coupled receptor and methods of use
KR102405099B1 (ko) 2015-04-13 2022-06-07 화이자 인코포레이티드 치료 항체 및 그의 용도
CA2980189A1 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
TWI781108B (zh) * 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
WO2018117786A1 (es) 2016-12-19 2018-06-28 Campo Y Ramos Juan Carlos Método de moldeo científico autoajustado por aprendizaje recurrente en tiempo real
KR20190133160A (ko) * 2017-02-07 2019-12-02 다이이찌 산쿄 가부시키가이샤 항-gprc5d 항체 및 항-gprc5d 항체를 포함하는 분자
TWI829667B (zh) * 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
CA3100157A1 (en) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
MX2021007307A (es) * 2018-12-21 2021-07-07 Hoffmann La Roche Anticuerpos que se unen a cd3.
MA54513A (fr) * 2018-12-21 2022-03-30 Hoffmann La Roche Molécules de liaison à l'antigène cd28 agonistes de ciblage de tumeurs

Also Published As

Publication number Publication date
JP2022543553A (ja) 2022-10-13
CA3144524A1 (en) 2021-02-04
AU2020323686A1 (en) 2021-11-11
EP4003526A2 (en) 2022-06-01
CN114174342A (zh) 2022-03-11
WO2021018859A2 (en) 2021-02-04
CO2022000803A2 (es) 2022-02-07
IL287613A (en) 2021-12-01
AR119553A1 (es) 2021-12-29
TW202112823A (zh) 2021-04-01
WO2021018859A3 (en) 2021-05-14
KR20220028035A (ko) 2022-03-08
AU2020323686B2 (en) 2024-03-21
MX2022001156A (es) 2022-02-22
US20220259318A1 (en) 2022-08-18
CR20220019A (es) 2022-02-11
JP2023175704A (ja) 2023-12-12
CL2022000127A1 (es) 2022-10-28
BR112022001460A2 (pt) 2022-03-22
SG11202112491WA (en) 2021-12-30

Similar Documents

Publication Publication Date Title
PE20220394A1 (es) Anticuerpos que se fijan a gprc5d
CO2017003048A2 (es) Moléculas de unión a antígeno biespecíficas activadoras de células t que se unen a cd3 y al receptor 1 de folato (folr1)
CL2023002239A1 (es) Anticuerpos de b7-h4 y métodos para usarlos
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
MX2021007320A (es) Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor.
CL2020003028A1 (es) Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos.
PE20160716A1 (es) Anticuerpo anti-tweakr y sus usos
PE20170263A1 (es) Moleculas biespecificas de union a antigeno activadoras de celulas t
PE20201341A1 (es) Anticuerpos de union a gprc5d
PE20191846A1 (es) Anticuerpos especificos para flt3 y sus usos
CO2018001485A2 (es) Diacuerpos monovalentes biespecificos que son capaces de unirse a b7 - h3 y cd3
CO2017010495A2 (es) Anticuerpos que se unen a bcma y/o cd3
EA201691925A1 (ru) Биспецифические антитела, которые связываются с cd38 и cd3
PE20180330A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y metodos para su uso
AR106201A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
PE20181044A1 (es) Anticuerpos anti-pd-1 y composiciones
PE20220278A1 (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d
ECSP17047155A (es) Productos farmacéuticos y composiciones líquidas estables de anticuerpos contra il-17
PE20200152A1 (es) Receptores de union a antigeno mejorados
AR063090A1 (es) Proteinas de union al antigeno del receptor de la il-17
EA201891502A1 (ru) Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
BR112016014810A2 (pt) Antagonistas de fcrn e métodos de uso
CL2017003039A1 (es) Anticuerpos que une a los ligandos calidina y des-arg10-calidina del receptor b1 de bradicina, método de producción del anticuerpo, composición farmacéutica que lo contiene y uso para el tratamiento del dolor. (divisional solicitud 2590-2014)
BR112017024555A2 (pt) moduladores de ccr2
BR112021023345A2 (pt) Imunotolerância com alvo em madcam